MX2019012144A - Arn para tratamiento de enfermedades autoinmunitarias. - Google Patents
Arn para tratamiento de enfermedades autoinmunitarias.Info
- Publication number
- MX2019012144A MX2019012144A MX2019012144A MX2019012144A MX2019012144A MX 2019012144 A MX2019012144 A MX 2019012144A MX 2019012144 A MX2019012144 A MX 2019012144A MX 2019012144 A MX2019012144 A MX 2019012144A MX 2019012144 A MX2019012144 A MX 2019012144A
- Authority
- MX
- Mexico
- Prior art keywords
- rna
- treatment
- autoimmune diseases
- autoantigen
- development
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a ARN no inmunogénico. Este ARN forma la base para el desarrollo de agentes terapéuticos para inducir tolerancia hacia un autoantígeno y, por lo tanto, para el tratamiento de enfermedades autoinmunitarias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2017/058651 WO2018188730A1 (en) | 2017-04-11 | 2017-04-11 | Rna for treatment of autoimmune diseases |
PCT/EP2018/059188 WO2018189193A1 (en) | 2017-04-11 | 2018-04-10 | Rna for treatment of autoimmune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019012144A true MX2019012144A (es) | 2019-11-21 |
Family
ID=58632945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019012144A MX2019012144A (es) | 2017-04-11 | 2018-04-10 | Arn para tratamiento de enfermedades autoinmunitarias. |
Country Status (22)
Country | Link |
---|---|
US (2) | US11701413B2 (es) |
EP (2) | EP3981424A1 (es) |
JP (3) | JP7078641B2 (es) |
KR (2) | KR20190134765A (es) |
CN (2) | CN110719787B (es) |
AU (1) | AU2018253352A1 (es) |
BR (1) | BR112019020667A8 (es) |
CA (1) | CA3059505A1 (es) |
CY (1) | CY1124767T1 (es) |
DK (1) | DK3609529T3 (es) |
ES (1) | ES2893451T3 (es) |
HR (1) | HRP20211559T1 (es) |
HU (1) | HUE056871T2 (es) |
IL (2) | IL269793B (es) |
LT (1) | LT3609529T (es) |
MX (1) | MX2019012144A (es) |
PL (1) | PL3609529T3 (es) |
PT (1) | PT3609529T (es) |
RS (1) | RS62582B1 (es) |
SG (2) | SG11201909520VA (es) |
SI (1) | SI3609529T1 (es) |
WO (2) | WO2018188730A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020102172A2 (en) * | 2018-11-12 | 2020-05-22 | Translate Bio, Inc. | Methods for inducing immune tolerance |
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
US11161892B1 (en) | 2020-12-07 | 2021-11-02 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
CN115232825B (zh) * | 2021-04-22 | 2023-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种基于1083骨架的新冠病毒疫苗 |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
BR112023024116A2 (pt) | 2021-05-26 | 2024-02-06 | Imcyse Sa | Métodos de tratamento ou prevenção de doenças autoimunes |
AR126654A1 (es) | 2021-06-29 | 2023-11-01 | Imcyse Sa | Péptidos y métodos para el tratamiento de neuromielitis óptica |
CN113336862B (zh) * | 2021-07-05 | 2022-03-01 | 广东省科学院动物研究所 | 一种抗多发性硬化的重组蛋白及其制备方法和用途 |
WO2023030635A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
CN118369335A (zh) * | 2022-01-06 | 2024-07-19 | 上海吉量医药工程有限公司 | N1位修饰假尿嘧啶核苷及其在mRNA合成中的应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030098B2 (en) * | 1999-03-12 | 2006-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for treatment of autoimmune disease |
AU2002952834A0 (en) * | 2002-09-16 | 2002-12-05 | The Walter And Eliza Hall Institute Of Medical Research | A method of treating an autoimmune disease |
ES2735531T3 (es) | 2005-08-23 | 2019-12-19 | Univ Pennsylvania | ARN que contiene nucleósidos modificados y métodos de uso del mismo |
US9012219B2 (en) * | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
EP2050814A1 (en) | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
SG181564A1 (en) * | 2009-12-07 | 2012-07-30 | Katalin Kariko | Rna preparations comprising purified modified rna for reprogramming cells |
WO2012154933A1 (en) * | 2011-05-10 | 2012-11-15 | The Brigham And Women's Hospital, Inc. | Detecting inclusion body myositis |
WO2013044419A1 (en) * | 2011-09-30 | 2013-04-04 | Beijing Advaccine Biotechnology Co., Ltd. | Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases |
EP2798064B1 (en) | 2011-12-30 | 2016-08-31 | Cellscript, Llc | Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect |
WO2013120498A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
CA2984125A1 (en) * | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
CN106395552B (zh) * | 2015-08-03 | 2020-03-17 | 奥的斯电梯公司 | 无绳电梯***导轨组件 |
AU2016315444B2 (en) * | 2015-08-28 | 2023-02-23 | BioNTech SE | Method for reducing immunogenicity of RNA |
ES2900272T3 (es) * | 2016-04-22 | 2022-03-16 | BioNTech SE | Métodos para proporcionar ARN monocatenario |
-
2017
- 2017-04-11 WO PCT/EP2017/058651 patent/WO2018188730A1/en active Application Filing
-
2018
- 2018-04-10 HR HRP20211559TT patent/HRP20211559T1/hr unknown
- 2018-04-10 HU HUE18717580A patent/HUE056871T2/hu unknown
- 2018-04-10 KR KR1020197033154A patent/KR20190134765A/ko not_active Application Discontinuation
- 2018-04-10 EP EP21191317.3A patent/EP3981424A1/en active Pending
- 2018-04-10 EP EP18717580.7A patent/EP3609529B1/en active Active
- 2018-04-10 SI SI201830424T patent/SI3609529T1/sl unknown
- 2018-04-10 PL PL18717580T patent/PL3609529T3/pl unknown
- 2018-04-10 ES ES18717580T patent/ES2893451T3/es active Active
- 2018-04-10 AU AU2018253352A patent/AU2018253352A1/en active Pending
- 2018-04-10 BR BR112019020667A patent/BR112019020667A8/pt unknown
- 2018-04-10 JP JP2019555957A patent/JP7078641B2/ja active Active
- 2018-04-10 US US16/500,005 patent/US11701413B2/en active Active
- 2018-04-10 SG SG11201909520V patent/SG11201909520VA/en unknown
- 2018-04-10 DK DK18717580.7T patent/DK3609529T3/da active
- 2018-04-10 PT PT187175807T patent/PT3609529T/pt unknown
- 2018-04-10 RS RS20211224A patent/RS62582B1/sr unknown
- 2018-04-10 MX MX2019012144A patent/MX2019012144A/es unknown
- 2018-04-10 CA CA3059505A patent/CA3059505A1/en active Pending
- 2018-04-10 CN CN201880024391.7A patent/CN110719787B/zh active Active
- 2018-04-10 CN CN202410206779.6A patent/CN118161602A/zh active Pending
- 2018-04-10 KR KR1020247008874A patent/KR20240042138A/ko active Search and Examination
- 2018-04-10 SG SG10202111163VA patent/SG10202111163VA/en unknown
- 2018-04-10 WO PCT/EP2018/059188 patent/WO2018189193A1/en unknown
- 2018-04-10 LT LTEPPCT/EP2018/059188T patent/LT3609529T/lt unknown
-
2019
- 2019-10-03 IL IL269793A patent/IL269793B/en unknown
-
2021
- 2021-10-06 CY CY20211100867T patent/CY1124767T1/el unknown
-
2022
- 2022-02-28 IL IL290980A patent/IL290980A/en unknown
- 2022-05-19 JP JP2022082384A patent/JP7444924B2/ja active Active
-
2023
- 2023-06-12 US US18/333,273 patent/US20230330198A1/en active Pending
-
2024
- 2024-02-22 JP JP2024025246A patent/JP2024059794A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019012144A (es) | Arn para tratamiento de enfermedades autoinmunitarias. | |
IL272410A (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
PH12019501959A1 (en) | Therapeutic rna | |
CA193736S (en) | Skin massager | |
MX2023010042A (es) | Polinucleotidos moduladores. | |
MX2020003425A (es) | Tratamiento de trastornos inflamatorios. | |
MX2018012880A (es) | Metodos para proporcionar arn de hebra sencilla. | |
MX2018008515A (es) | Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones inmunitarias. | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
EA201891202A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201891201A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890050A1 (ru) | Композиции, содержащие бактериальные штаммы | |
EA201890049A1 (ru) | Композиции, содержащие бактериальные штаммы | |
GEP20217252B (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
PH12019500494A1 (en) | Formulations of (r)-2-amino-3-phenylpropyl carbamate | |
MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
EA201991997A1 (ru) | Комбинированная терапия | |
IL269895B2 (en) | Coversin for the treatment of autoimmune blistering diseases | |
MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
MX2020013389A (es) | Composiciones de terlipresina y usos de las mismas. | |
MX2020004662A (es) | Ajuste planificado del contorno mediante especificaciones correspondientes. | |
ZA202105101B (en) | Peptides for treatment and prevention of diabetes and associated disorders | |
MX2018007408A (es) | Uso de adyuvantes para la prevencion y/o el tratamiento de enfermedades autoinmunes. | |
MX2019000600A (es) | Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello. | |
MX2017013879A (es) | Composiciones que comprenden anakinra. |